Valdecoxib
- Generic Name
- Valdecoxib
- Brand Names
- Bextra
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14N2O3S
- CAS Number
- 181695-72-7
- Unique Ingredient Identifier
- 2919279Q3W
- Background
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
- Indication
For the treatment of osteoarthritis and dysmenorrhoea
- Associated Conditions
- Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis
- Associated Therapies
- -
Double-Blind, Randomized Study Of The Analgesic Efficacy And Safety Of Valdecoxib 20 Mg Daily And Valdecoxib 20 Mg Twice Daily Compared To Placebo For Management Of Acute Postsurgical Pain In Anterior Cruciate Ligament (ACL) Reconstruction
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 488
- Registration Number
- NCT00650039
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Weston, Ontario, Canada
A Comparison Of Valdecoxib 20 Mg Twice Daily and 40 Mg Daily and Placebo In The Treatment Of Sore Throat
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 197
- Registration Number
- NCT00647829
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Boca Raton, Florida, United States
Randomized, Double Blind, Multicenter Study of the Safety and Efficacy of Valdecoxib 40 mg Once Daily Compared With Diclofenac 75 mg Twice Daily in Acute Low Back Pain
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 340
- Registration Number
- NCT00649610
- Locations
- ๐ป๐ช
Pfizer Investigational Site, Caracas, Venezuela
Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2008-07-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 489
- Registration Number
- NCT00650455
- Locations
- ๐จ๐ฆ
Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada
Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2009-01-29
- Target Recruit Count
- 371
- Registration Number
- NCT00419549
- Locations
- ๐ฎ๐ณ
All India Institute of Medical Sciences, New Delhi, India
Effect of Valdecoxib Pretreatment on Pain and Secondary Hyperalgesia in Healthy Volunteers
- Conditions
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Penn State University
- Target Recruit Count
- 20
- Registration Number
- NCT00260325
- Locations
- ๐บ๐ธ
Penn State University College of Medicine, Hershey, Pennsylvania, United States
Perioperative Inflammation and Cyclooxygenase 2 (COX-2)
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-09-26
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 30
- Registration Number
- NCT00122096
- Locations
- ๐บ๐ธ
University of Washington, Seattle, Washington, United States
Genetic Basis For Variation In NSAID Analgesia In A Clinical Model Of Acute Pain
- Conditions
- First Posted Date
- 2005-06-24
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institute of Nursing Research (NINR)
- Target Recruit Count
- 96
- Registration Number
- NCT00115752
- Locations
- ๐บ๐ธ
National Institute of Nursing Research (NINR), Bethesda, Maryland, United States
Valdecoxib in Treating Chronic Pain in Cancer Patients
- Conditions
- First Posted Date
- 2004-02-27
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT00021996
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.